Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
OBJECTIVE
To compare the efficacy of each of seven expressed herpes simplex virus 1 (HSV-1) glycoproteins as vaccines to protect against ocular disease after primary ocular HSV-1 infection.


METHODS
Mice were vaccinated three times with equal amounts of each of seven individually expressed HSV-1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI) and then ocularly challenged with McKrae, a corneal disease-producing strain of HSV-1. Viral clearance from the eye, blepharitis, keratitis, and neovascularization were determined at various times after infection.


RESULTS
Mice vaccinated with gD or gB had the best protection against eye disease. Vaccination with gI, gC, or gE produced moderate protection against eye disease. Vaccination with gG produced less protection, and vaccination with gH produced no apparent protection against eye disease.


CONCLUSIONS
These results suggest that when used as vaccines, different HSV-1 glycoproteins provide different levels of protection against HSV-1-induced eye disease. Based on comparison with the authors' previously published results, the ability of each glycoprotein to protect against eye disease correlated with the ability of the glycoprotein to induce high serum neutralizing antibody titers and killer cell activity. Results suggest that the effectiveness of these seven glycoproteins in protecting against eye disease can be ranked as follows: gD > gB > gI > (gC = gE) > gG > gH.
Ghiasi
H
H
Department of Ophthalmology Research, Cedars-Sinai Medical Center Research Institute, Los Angeles, CA 90048, USA.
Bahri
S
S
Nesburn
A B
AB
Wechsler
S L
SL
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D001762:Blepharitis / Q000382:microbiology / Q000517:prevention & control; D003315:Cornea / Q000276:immunology / Q000382:microbiology; D016510:Corneal Neovascularization / Q000517:prevention & control; D005260:Female; D018259:Herpesvirus 1, Human / Q000276:immunology* / Q000502:physiology; D016849:Keratitis, Herpetic / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D014611:Vaccination; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage*
D000914:Antibodies, Viral; D014759:Viral Envelope Proteins; D014765:Viral Vaccines